Across TCGA pan-cancer cohorts, MIR1179 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR1179 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR1179 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR1179 expression acts as an unfavorable survival marker.
SKCM are the cancer types where MIR1179 Mutation most reproducibly stratifies survival.